The Epidemiology of Venous Thrombosis

• REFERENCES

• 1 Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briët E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993; 341: 134-138.
• 2 Alpert JS, Dalen JE. Epidemiology and natural history of venous thromboembolism. Prog Cardiovasc Dis 1994; 36: 417-22.
• 3 Anderson FA, Wheeler HB, Goldberg RJ. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933-8.
• 4 Awidi AS, Abu-Khalaf M, Herzallah U, Abu-Rajab A, Shannak MM, Abu-Obeid T, Al-Taher I, Anshasi B. Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan. Am J Hematol 1993; 44: 95-100.
• 5 Bergqvist D. Frequency of thromboembolic complications. In: Bergqvist D. Berlin: Springer; 1983: 12-3.
• 6 Bertina RM. Prevalence of hereditary thrombophilia and the identification of genetic risk factors. Fibrinolysis 1988; 02 (Supp. 2): 7-13.
• 7 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
• 8 Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Btiller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-6.
• 9 Brenner B, Zivelin A, Lanir N, Greengard JS, Griffin JH, Seligsohn U. Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C-deficient newborn with massive thrombosis. Blood 1996; 88: 877-80.
• 10 Brey RL, Coull BM. Cerebral venous thrombosis. Role of activated protein C resistance and factor V gene mutation. Stroke 1996; 27: 1719-20.
• 11 Carter CJ. The pathophysiology of venous thrombosis. Prog Cardiovasc Dis 1994; 36: 439-46.
• 12 Carter CJ. The natural history and epidemiology of venous thrombosis. Prog Cardiovasc Dis 1994; 36: 423-38.
• 13 Coon WW, Willis PW, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh community health study. Circulation 1973; 48: 839-46.
• 14 Cooper DN, Krawczak M. Venous Thrombosis; From Genes to Clinical Medicine. Oxford: BIOS Scientific Publishers; 1997
• 15 Coronary Drug Project Research Group. The coronary drug project: Initial findings leading to modifications of its research protocol. J Am Med Assoc 1970; 214: 1303-7.
• 16 Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CRM. The prothrombin gene G20210A variant: prevalence in a UK anticoagulant clinic population. Brit J Haematol 1997; 98: 353-5.
• 17 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
• 18 Dahlbäck B. Resistance to activated protein C, the Arg506 to Gin mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons. Thromb Haemost 1995; 73: 739-42.
• 19 D’Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11.
• 20 Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA. Thrombosis in antithrombin Ill-deficient persons. Report of a large kindred and literature review. Ann Int Med 1992; 116: 754-61.
• 21 den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocyst- einemia as a risk factor for deep vein thrombosis. New Engl J Med 1996; 334: 759-62.
• 22 De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes and management. 1996; Blood 87: 3531-44.
• 23 Desmarais S, de Moerloose P, Reber G, Minazio P, Perrier A, Bounameaux H. Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet 1996; 347: 1374-5.
• 24 Dolan G, Preston FE. Familial plasminogen deficiency and thromboembolism. Fibrinolysis 1988; 02 (Supp. 2): 26-34.
• 25 Drill VA, Calhoun DM. Oral contraceptives and thromboembolic disease. J Am Med Assoc 1968; 206: 77-84.
• 26 Engesser L, Brommer EJP, Kluft C, Briët E. Elevated plasminogen activator inhibitor (PAI), a cause of thrombophilia? A study in 203 patients with familial or sporadic venous thrombosis. Thromb Haemost 1989; 62: 673-80.
• 27 Falcon CR, Cattaneo M, Panzeri D, Marti-nelli I, Mannucci PM. High prevalence of hyperhomocysteinemia in patients with juvenile venous thrombosis. Arterioscl Thromb 1994; 14: 1080-3.
• 28 Fermo I, D’Angelo SV, Paroni R, Mazzola G, Calori G, D’Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995; 123: 747-53.
• 29 Fisher M, Fernandez JA, Ameriso SF, Xie D, Gruber A, Paganini-Hill A, Griffin JH. Activated protein C resistance in ischemic strike not due to factor V arginine glutamine mutation. Stroke 1996; 27: 1163-6.
• 30 Gandrille S, Greengard JS, Alhenc-Gelas M, Juhan-Vague I, Abgrall JF, Jude B, Griffin JH, Aiach M. Incidence of activated protein C resistance caused by the Arg 506 Gin mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. Blood 1995; 86: 219-24.
• 31 Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. New Engl J Med 1994; 331: 1601-6.
• 32 Gjores JE. The incidence of venous thrombosis and its sequelae in certain districts in Sweden. Acta Chir Scand 1956; 111: 16-24.
• 33 Goldberg RJ, Seneff M, Gore JM. Occult malignant neoplasms in patients with deep vein thrombosis. Arch Intern Med 1987; 147: 251-3.
• 34 Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506 —» Gin mutation in factor Va. Lancet 1994; 343: 1361-2.
• 35 Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
• 36 Halbmeyer W-M, Mannhalter C, Feichtin-ger C, Rubi K, Fischer M. The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost 1992; 68: 285-90.
• 37 Halbmeyer W-M, Haushofer A, Schön R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coag Fibrinol 1994; 05: 51-7.
• 38 Hallam PJ, Millar DS, Krawczak M, Kak-kar VV, Cooper DN. Population differences in the frequency of the factor V Leiden variant among individuals with clinically symptomatic protein C deficiency. J Med Genet 1995; 32: 543-5.
• 39 Heijboer H, Brandjes DPM, Büller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep vein thrombosis. New Engl J Med 1990; 323: 1512-6.
• 40 Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-4.
• 41 Hennekens CH, Buring JE. Epidemiology in Medicine. Boston: Little, Brown and Company; 1987
• 42 Hirsh J, Piovella F, Pina M. Congenital antithrombin III deficiency. Incidence and clinical features. Amer J Med 1989; 87 Suppl. 3B: 345-85.
• 43 Jeffcoate TNA, Miller J, Roos RF. Puerperal thromboembolism in relation to the inhibition of lactation by oestrogen therapy. Br Med J 1968; 04: 19-22.
• 44 Kawasaki T, Kambayashi J, Sakon M. Hyperlipidemia: a novel etiologic factor in deep vein thrombosis. Thromb Res 1995; 79: 147-51.
• 45 Kierkegaard A. Incidence and diagnosis of deep vein thrombosis associated with pregnancy. Acta Obstet Gynecol Scand 1983; 62: 239-43.
• 46 Kierkegaard A. Deep vein thrombosis and the oestrogen content in oral contraceptives - an epidemiological analysis. Contraception 1985; 31: 29-41.
• 47 Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-5.
• 48 Koeleman BPC, van Rumpt D, Hamulyak K, Reitsma PH, Bertina RM. Factor V Leiden: an additional risk factor for thrombosis in- protein S deficient families?. Thromb Haemost 1995; 74: 580-3.
• 49 Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
• 50 Koster T, Rosendaal FR, Briët E, Vandenbroucke JP. John Hageman’s factor and deep-vein thrombosis: Leiden Thrombophilia Study. Br J Haematol 1994; 87: 422-4.
• 51 Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briët E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. Thromb Haemost 1994; 71: 719-22.
• 52 Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
• 53 Koster T, Rosendaal FR, Briët E, van der Meer FJM, Colly LP, Trienekens PH, Poort SR, Reitsma PH, Vandenbroucke JP. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85: 2756-61.
• 54 Kraus M, Zander N, Fickenscher K. Coagulation assay with improved specificity to factor V mutants insensitive to activated protein C. Thromb Res 1995; 80: 255-64.
• 55 Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: Part 1. Thromb Haemost 1996; 76: 651-62.
• 56 Legnani C, Palaretti G, Biagi R, Coccheri S, Bernardl F, Rosendaal FR, Reitsma PH, De Ronde H, Bertina RM. Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation. Brit J Haematol 1996; 93: 694-9.
• 57 Leroy-Matheron C, Levent M, Pignon J-M, Mendonça C, Gouault-Heilmann M. The 1691 G^A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients. Thromb Haemost 1996; 75: 4-10.
• 58 Malinov MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med 1994; 236: 603-8.
• 59 Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiency. Sem Thromb Haemost 1990; 16: 299-309.
• 60 Mayo M, Halil T, Browse NL. The incidence of deep vein thrombosis after prostatectomy. Br J Urol 1971; 43: 738-42.
• 61 Melissari E, Monte G, Lindo VS, Pemberton KD, Wilson NV, Edmondson R, Das S, Kakkar VV. Congenital thrombophilia among patients with venous thromboembolism. Blood Coag Fibrinol 1992; 03: 749-58.
• 62 Miletich J, Sherman L, Broze G. Absence of thrombosis in subjects with heterozygous protein C deficiency. New Engl J Med 1987; 317: 991-6.
• 63 Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. Chap. 23 in The Metabolic Basis of Inherited Disease. 6th ed.. CR Scriver, Beaudet AL, WS Sly, Valle D. (Eds.) New York: McGraw-Hill; 1989
• 64 Nicolaides AN, Field ES, Kakkar VV. Prostatectomy and deep-vein thrombosis. Br J Surg 1972; 59: 487-8.
• 65 Nordstrom M, Lindblad B, Berqvist D. A prospective study of the incidence of deep- vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-60.
• 66 Olivieri A, Friso S, Manzato F, Guella A, Bernardi F, Lunghi B, Girelli D, Azzini M, Brocco G, Russo C, Corrocher R. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91: 465-70.
• 67 Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C or protein S deficiency. A cooperative, retrospective study. Arterioscler Thromb Vase Biol 1996; 16: 742-8.
• 68 Pabinger I, Schneider B, Scharrer I, Hach-Wunderle V, Lechner K, Eichinger S, Kyrle PA, Vinazzer H, Lämmle B, Demarmels-Biasiutti F, Tilsner V, Marx G, Seifried E, Gabelman A, Aspöck Fischer M, Halbmayer WM. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. Thromb Haemost 1994; 71: 548-52.
• 69 Pabinger I, Kyrle PA, Heistinger M, Eichinger S, Wittmann E, Lechner K. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study. Thromb Haemost 1994; 71: 441-5.
• 70 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 68: 3698-703.
• 71 Porter JB. Oral contraceptives and nonfatal vascular disease - recent experience. Obstet Gynecol 1982; 59: 299-302.
• 72 Prandoni P, Lensing AW, Buller HR. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. New Engl J Med. 1992. 327 1128-33.
• 73 Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute venous thrombosis. Ann Intern Med 1996; 125: 1-7.
• 74 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
• 75 Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpainter K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2.
• 76 Rintelen C, Pabinger I, Knöbl P, Lechner K, Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996; 75: 229-32.
• 77 Rintelen C, Mannhalter C, Ireland H, Lane DA, Knöbl P, Lechner K, Pabinger I. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol 1996; 93: 487-90.
• 78 Rosendaal FR, Bertina RM, Reitsma PH. Evaluation of activated protein C resistance in stored plasma. Lancet 1994; 343: 1289-90.
• 79 Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
• 80 Royal College of General Practioners’ Oral Contraception Study. Oral contraceptives, venous thrombosis, and varicose veins. J Roy Coll Gen Pract 1978; 28: 393-9.
• 81 Samsioe G. Coagulation and anticoagulation effects of contraceptive steroids. Am J Obstet Gynecol 1994; 170: 1523-7.
• 82 Samama MM, Simmoneau G, Wainstein JP. Sirius Study: epidemiology of risk factors for deep vein thrombosis (DVT) of the lower limbs in community practice. Thromb Haemost 1993; 69: 797A.
• 83 Sartori MT, Patrassi GM, Theodoridis P, Perin A, Pietrogrande F, Girolami A. Heterozygous type I plasminogen deficiency is associated with an increased risk for thrombosis: a statistical analysis in 20 kindreds. Blood Coag Fibrinol 1994; 05: 889-93.
• 84 Scarabin PY, Plu-Bureau G, Zitoun D, Bara L, Guize L, Samama MM. Changes in haemostatic variables induced by oral contraceptives containing 50 |xg or 30 |xg oestrogen: absence of dose-dependent effect of PAI-1 activity. Thromb Haemost 1995; 74: 928-32.
• 85 Schafer AI. Hypercoagulable states: molecular genetics to clinical practice. Lancet 1994; 344: 1739-42.
• 86 Stolley PD, Tonascia JA, Tockman MS. Thrombosis with low-estrogen oral contraceptives. Am J Epidemiol 1975; 102: 197-208.
• 87 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. New Engl J Med 1994; 330: 517-22.
• 88 Tabernero MD, Thomas JF, Alberca I, Or-fao A, Borrasca AL, Vincente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991; 36: 249-53.
• 89 Tait RC, Walker ID, Islam SIA, Mitchell R, Davidson JF. Plasminogen levels and putative prevalence of deficiency in 4500 blood donors (abstr.). Br J Haematol 1991; 77 Suppl.l: 10.
• 90 Tait RC, Walker ID, Perry DJ, Islam SIAM, Daly ME, McCall F, Conkie JA, Carrell RW. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106-12.
• 91 Tait RC, Walker ID, Reitsma PH, Islam SIAM, McCall F, Poort SR, Conkie JA, Bertina RM. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995; 73: 87-93.
• 92 Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-con- trol study. Int J Epidemiol 1992; 21: 48-52.
• 93 Tuddenham EGD, Takase T, Thomas AE, Awidi AS, Madanat FF, AbuHajir MM, Kernoff PBA, Hoffbrand AV. Homozygous protein C deficiency with delayed onset of symptoms at 7 to 10 months. Thromb Res 1989; 53: 475-84.
• 94 Tuddenham EGD, Cooper DN. The Molecular Genetics of Haemostasis and its Inherited Disorders. Oxford: Oxford University Press; 1994
• 95 van Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdhury V, Bauer KA, Scharrer I, Conard J, Lane DA. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75: 417-21.
• 96 Vandenbroucke IP, Koster T, Briët E, Reitsma PH, Rosendaal FR. Increased risk of venous thrombosis in oral- contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
• 97 Voorberg J, Roelse J, Koopman R, Büller H, Berends F, ten Cate JW, Mertens K, van Mourik JA. Association of idiopathic venous thromboembolism with single pointmutation at Arg506 of factor V. Lancet 1994; 343: 1535-6.
• 98 Walsh JJ, Bonnar J, Wright FW. A study of pulmonary embolism and deep vein thrombosis after major gynaecological surgery using labelled fibrinogen-phlebography and lung scanning. J Obstet Gynaecol Br Com- monw 1974; 81: 311-6.
• 99 World Health Organization Collaborative Study of Cardivascular Disease Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-82.
• 100 Zöller B, He X, Dahlbäck B. Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease. Thromb Haemost 1994; 73: 743-5.
• 101 Zöller B, Berntsdottir A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.